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Introduction
The heterotetrameric kinesin-1 microtubule motor plays a crucial role in spatial organization of many subcellular components by virtue of its capacity to transport diverse protein and ribonuclear protein complexes, vesicles and organelles on microtubules (1) (2) (3) (4) . Kinesin-1 also regulates the organization of the microtubule network itself, through its ability to mediate microtubule-microtubule interactions that result in their bundling and sliding (5) (6) (7) (8) (9) . This activity is important for cytoplasmic streaming in drosophila oocytes, formation of microtubule based cellular processes and axonal regeneration (5, 10) .
These diverse functions rely on a capacity to translocate with high processivity towards the plus(+)end of microtubules imparted by the microtubule binding amino terminal ATPase motor domains of the dimeric kinesin heavy chains (KHCs) and a multivalent cargo binding domain comprised of the C-terminal domains of the KHCs and the kinesin light chains (KLCs), which contain binding sites for both organellespecific cargo adaptors and microtubules (9, (11) (12) (13) (14) (15) .
In the absence of cargo, kinesin-1 is in an autoinhibited, folded conformation that is stabilized by the interaction of a single C-terminal KHC tail with the motor domain dimer interface, thereby crosslinking the two motor domains and preventing futile cycles of ATP hydrolysis (16) (17) (18) (19) (20) (21) (22) . We have recently shown that the KLCs, which regulate kinesin-1 activity (23, 24), also engage, in cis, in a second autoinhibitory intramolecular interaction between their tetratricopeptide repeat domain (KLC TPR ) and a negatively charged unstructured linker region immediately preceding it carrying a leucine-phenylalanineproline (LFP) motif (25). Binding of organelle-specific cargo adaptors containing 'W-acidic' short-linearpeptide motifs to KLC TPR , which can initiate kinesin-1 activation (11, 26, 27) , displaces this intramolecular interaction causing a conformational change within the KLCs (25). We proposed that this cargo dependent conformational change acts a molecular switch to control the activity of the holoenzyme (25). We also recently provided evidence to suggest that one consequence of W-acidic motif engagement of KLC TPR is to make a cargo binding site in the KHC tail, that is inaccessible in the autoinhibited conformation, available to bind cargo (28). The predominantly basic series of amino acids comprising this site can interact with closely related cargo adaptors sequences to stabilize the kinesin-1-cargo interaction and interestingly, is also known to interact with microtubules in an ATP-independent manner (9, 14, 15, 19) . Collectively, these data suggest a stepwise model for kinesin-1 activation, in which engagement of KLC TPR and resulting light chain conformational change, is the key upstream signal to activate kinesin-1, and, in a context dependent manner, results in either organelle transport, if KHC interacts with an organelle cargo adaptor(28), or microtubule bundling and sliding, if KHC interacts with microtubules. In support of such a proposition, the KLCs have been demonstrated to modulate the affinity of the KHC-tail for microtubules in a manner dependent on the KLC LFP-acidic linker region (24), and the W-acidic motif containing kinesin-1 adaptor calsyntenin-1 was recently shown to play a role in regulating microtubule organization in dendritic arbor development (29). One prediction of such a model is that if kinesin-1 were to be activated under conditions where its capacity to interact with organelles was limited, its role in microtubule sliding and bundling would be promoted.
We employed a chemical biology based approach to test this hypothesis, seeking to identify small molecules that could induce KLC TPR dependent kinesin-1 activation in the absence of organelle cargo adaptor engagement. This resulted in the identification of a compound that we have named kinesore, which in vitro, inhibits the interaction of KLC TPR with the W-acidic lysosomal cargo adaptor SKIP. We
show that in cells, kinesore induces the light chain conformational switch in a similar manner to activating cargo and causes the large-scale kinesin-1 dependent remodeling of the microtubule network.
Thus, we demonstrate that the organelle transport and microtubule sliding/bundling functions of the motor are coupled through a shared activation mechanism. Moreover, we establish a proof-of-concept that a microtubule motor-cargo interface and associated autoregulatory mechanism can be manipulated using a small molecule, and offer an unexpected new target for the modulation of microtubule dynamics. We developed a primary in vitro time-resolved (TR) FRET assay ( Figure 1A , top) coupled to a secondary fluorescence polarization (FP) based assay ( Figure 1A , middle) to identify compounds that had the capacity to inhibit the interaction between aiKLC2 TPR and SKIP WD and screened the 2908 compound Chemogenomic Library provided by Pfizer (see materials and methods for details). A tertiary FP screen of compounds from the Hit-2-Lead library (Chembridge), informed by this dataset, resulted in the
Results
Identification of kinesore as a small molecule inhibitor of the KLC2 -SKIP interaction
hydroxybenzohydrazide, hereafter named kinesore ( Figure 1A , bottom).
Consistent with its ability to target the kinesin-1-cargo interface, in pull down assays, kinesore inhibited the interaction between purified recombinant GST-SKIP(1-310) and full length haemaglutinin(HA)-KLC2 with a 50% reduction in binding at 12.5μM and elimination of any detectable binding at a 25μM kinesore ( Figure 1B) . In FP assays, kinesore inhibited the interaction of TAMRA-SKIP WD with aiKLC2 TPR in a concentration dependent manner ( Figure 1C ) (30). Based upon this activity profile, and penetrant cellular phenotype described below, we decided to pursue it further. To the best of our knowledge, this compound has not been characterised before in any other context.
Kinesore remodels the microtubule network
To examine the effect of kinesore in cells, HeLa cells were treated with 50μM kinesore for one hour. As Formally testing the kinesin-1 dependence of kinesore induced remodeling of microtubules is complicated by the multiple genes that can encode KHC (Kif5A, Kif5B, Kif5C) and KLC (KLC1, KLC2, KLC3, KLC4) which have distinct cell and tissue expression profiles and which have the potential to undergo compensatory changes in expression following loss of a specific isotype (34). To address this, we used the commercially available KHC (KIF5B) CRISPR knockout, chronic myeloid leukemia (CML) derived HAP1 cell line, and matched wild type control. In wild type HAP1 cells, transcriptomic data suggest that Kif5B is the predominant isotype at 61 transcripts per million (TPM). Kif5C is present at 21 TPM whilst Kif5A is not expressed (35). Consistent with this, Kif5B was detected in wild type cell extracts using a Kif5B-specific polyclonal antibody, but was absent in Kif5B KO cells. In contrast, pan-KHC antibody revealed a substantial but not complete reduction in total KHC expression, suggesting the presence of lower levels of another isotype ( Figure 3C ). In wild type cells, 50μM kinesore induced the remodeling of the microtubule network and the formation of extensive microtubule-rich projections. This phenotype was strongly suppressed in Kif5B knockout cells, confirming that microtubule remodeling induced by kinesore is dependent upon the presence of kinesin-1.
Kinesore induces the light chain conformational switch
These data suggest that kinesore, by engaging the KLC TPR in a manner that inhibits interactions of kinesin-1 with activating cargo adaptors, may act in a 'cargo-mimetic' manner to promote kinesin-1 activation. To test this hypothesis, we employed our previously validated KLC conformation biosensor 
Discussion
Kinesin family proteins play key roles in both cargo transport on microtubules and in controlling microtubule dynamics to support a wide range of cellular processes (3, 36) . Some, such as the kinesin-4 family member Kif21B possess both of these capacities which are fine tuned for its function (37) . Is has been appreciated for many years that kinesin-1 also possesses both of these abilities (6) . However, the molecular mechanisms that underpin and regulate the balance between these two activities and their relationship to kinesin-1 autoinhibition remain largely unknown. Here we have employed a chemical biology driven approach to test the hypothesis that these functions are linked though a common regulatory mechanism. Our identification of kinesore as a small molecule that inhibits the SKIP-KLC2 interaction in vitro yet promotes kinesin-1 function in controlling the organization of the microtubule network in cells strongly supports our hypothesis. Moreover, the data provides proof-of-concept that a microtubule motorcargo interface and associated autoregulatory mechanism can be manipulated using a small molecule, and defines a potential new target for the modulation of microtubule dynamics.
Collectively, our data suggest a model in which kinesore engages the KLCs of kinesin-1 in cargolike fashion to initiate crucial events in cargo-dependent activation, the net result of which is to promote the function of the motor in regulating microtubule bundling and sliding, leading to the remodeling of the microtubule network
Our favored model builds upon our recent studies (11, 25, 28) kinesin-1 to perform its role in promoting bundling and sliding, resulting in the formation of loops and bundles that bear a notable resemblance to those previously observed following over-expression of an active microtubule sliding kinesin-14 family member (32). Bundling of parallel microtubules and sliding of antiparallel microtubules (6) in the background of continuing + end dynamics progressively leads to the emergence of the complex phenotypes observed.
It is worth stating explicitly that we make no claim regarding the specificity of kinesore outside of this limited functional space. Given that the compound must be used at relatively high concentrations in cells (25 -50μM) it is highly likely that other cellular targets exist, although it is unlikely that these make a significant contribution to the microtubule phenotype described. We have not observed any direct effects in vitro on tubulin polymerization suggesting that this not likely a major component of the cellular activity of kinesore, however, we cannot rule out the possibility of a synergistic direct or indirect activity that combines with the compound's effect on kinesin-1, that is not captured in these assays.
Nonetheless, it is worth reflecting on the proof-of-concept established here. To our knowledge this is the first time that the cargo-binding interface and associated autoregulatory mechanism of a cytoskeletal motor has been targeted using a small molecule. We suggest that this offers several exciting possibilities for the future. Most small molecules that modulate cytoskeletal motor protein function target the ATPase activity or motility mechanisms associated with motor domains that are relatively well conserved within the kinesin, myosin and dynein families, thus hindering the development of specific functional modulators. In contrast, although autoregulation coupled to cargo recognition represent common themes, the mechanisms by which this is achieved are quite divergent (3, (38) (39) (40) (41) . For example, kinesin-1 is the only kinesin family member that employs a TPR domain-short linear motif cargo recognition mechanism (11) which is coupled to its autoregulatory mechanism (25). Indeed, this makes it very unlikely that kinesore has activity against any other kinesin family member. Thus, targeting of these mechanisms may represent a novel approach to achieving small molecule control of motor protein function for use as both research tools and for potential therapeutic purposes where motor proteins are dysregulated. Importantly, this approach offers the prospect of not only inhibiting, but also enhancing specific motor protein activities. Developments over recent years establishing the structural basis for cargo recognition and autoregulation are an essential prerequisite for this approach: myosin V, MCAK, cytoplasmic dynein and dynein-2 all represent potential candidates where structural and biophysical analysis allows one to consider similar in vitro screening based approaches to target core cargo recognition and autoregulatory mechanisms (38, 39, (42) (43) (44) . Other candidates and mechanisms in all three families will surely emerge as studies continue to define the molecular underpinnings of these processes.
Finally, it is worth considering the potential of the kinesin-1-cargo interface itself as a drug target.
Microtubule targeting agents (stabilizers and destabilizers) represent an important class of chemotherapeutics, but are limited by issues of both toxicity and resistance. Molecules that offer a mechanistically distinct approach to the modulation of microtubule dynamics are actively sought (45) . It is conceivable that a molecule that bound the kinesin-1 cargo interface with both high affinity and selectivity, and elicited similar effects to kinesore, could represent such a drug. One might also consider whether manipulation of kinesin-1 activity could be advantageous in neurological conditions where axonal transport is impaired (46) . Clearly therefore a structural understanding of the kinesore mechanism is imperative as this would facilitate rational design and phenotypic screening approaches.
Materials and Methods
Expression, purification and Terbium labelling of aiKLC2 TPR His-KLC2 161-480 (aiKLC2 TPR ) protein was expressed in BL21 E.coli, isolated by nickel affinity chromatography and further purified by size-exclusion chromatography in 500mM NaCl as previously described (25). 10ml of 100 μM (1 μmole) purified protein was dialysed overnight at 4°C into a labelling buffer comprising 100mM Na 2 CO 3 and 150mM NaCl at pH 9. 340nm. This mix of labelled and non-labelled aiKLC2 was then dialysed overnight at 4°C into 25mM HEPES (pH 7.5), 150mM NaCl, 5 mM β-ME buffer in preparation for use in the TR-FRET screen.
See SI materials and methods for additional materials and methods
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v/v and compound concentration of 49.4μM). Plates were incubated at room temperature for 30 minutes and subsequently analysed using a Artemis TR-FRET K-101 plate reader (Kyoritsu Radio Co., Ltd.) at an excitation wavelength of 340nm, measuring FRET as a ratio of 665 nm (acceptor) to 620nm (donor) emission intensity, with a time delay of 100 μsec following excitation. TR-FRET ratio was normalised to in plate DMSO controls.
Compounds that elicited a decrease in TR-FRET ratio that fell outside of a fitting of a normal distribution to the data (50 compounds) were selected for further analysis.
Compounds with inconsistent duplicates were disregarded.
FP assay for secondary and tertiary screens
Fluorescence polarisation (FP) experiments for the purpose of secondary screening were performed in duplicate in black non-binding 96-well plates with flat bottomed wells (Corning, 655900). 50 compounds identified from the initial TR-FRET assay were supplied prealiquoted on plates in a 1μl volume at a concentrations of 0.25mM -4mM, and tested in a 2 fold dilution series, giving final reaction concentrations ranging from 3.5 -57μM. 70μl of a master mix solution containing 8μM non-labelled aiKLC2 TPR produced as described above, 150nM TAMRA conjugated SKIP WD peptide (11). 25mM HEPES (pH 7.5), 150mM NaCl, 5mM β-ME were added to each well (giving a final 
Plasmids, antibodies and cells
All bacterial and mammalian expression plasmids used in this study have been described previously (11, 25) . FRET biosensor plasmids are described in ( Spectrum projection images in figure 2E were generated using the Time-lapse colour coder Image J plugin.
FRET/FLIM Sample Preparation and Data Acquisition.
FRET biosensor studies were carried out as previously described, using a updated (Scale bars: 10 μm.).
Fig. S3
Nocodazole disrupts kinesore induced loops and bundles. HeLa cells were treated with (left) DMSO control for 60 minutes, followed by 10 μM nocodazole, (middle) 50μM kinesore for 90 mins, or (right) 50μM kinesore for 60 minutes followed by 10 μM nocodazole + 50μM kinesore for 30 minutes. 
Fig. S7
Effect of kinesore on association of GFP-KIf5B (N-FLAP) association with microtubules.
Cells were lysed in a microtubule stabilizing buffer following 1 hour treatment with kinesore at 50μM and lysates were subjected to centrifugation to pellet polymerised microtubules and associated proteins. Pellets and supernatant fractions were analysed by western blot for GFP (Kif5B/KHC) and tubulin. Graph shows quantification of protein in pellet fractions from 3 independent experiments, following normalisation to control. Error bars show ±SEM. * indicates p<0.05 obtained using 2-tailed t-test. ns = not significant.
Movie S1
Confocal image sequence at 5 second intervals for 9 minutes of HeLa cells stably expressing GFP-tubulin and treated with 50μM kinesore for 1 hour. Image sequence begins after 1 hour of treatment.
Movie S2 and S3
Spinning disk confocal image sequences at 5 second intervals for 2 minutes of HeLa cells stably expressing EB3-RFP in control conditions (S1) or treated with 50μM kinesore for 1 hour (S2).
